Inhibikase Therapeutics has sold 25 million shares of common stock to RA Capital Management through its at-the-market facility, raising $50 million in gross proceeds. The new capital, combined with existing reserves, will fund operations through the topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH study, pending full exercise of outstanding Series A and B warrants. The financing was executed under a shelf registration statement declared effective by the SEC in June 2025, with a prospectus supplement filed in December 2025. Inhibikase's lead candidate, IKT-001, is a prodrug of imatinib mesylate being developed for Pulmonary Arterial Hypertension, a progressive and life-threatening disease affecting about 50,000 Americans. The pivotal Phase 3 IMPROVE-PAH trial is enrolling patients across roughly 180 sites worldwide.
Inhibikase Therapeutics IncRaised $50M from RA Capital Management, extending cash runway through Phase 3 data readout.